𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Farnesoid X receptor (FXR) status complements the evaluation of estrogen receptor alpha (ER) in breast cancer (BC) patients and predicts benefit from tamoxifen

✍ Scribed by F. Journe; V. Durbecq; B. Haibe-Kains; C. Chaboteaux; G. Rouas; G. Laurent; D. Larsimont; M. Piccart; J.J. Body; C. Sotiriou


Book ID
119598028
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
56 KB
Volume
6
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.